| Not Yet Recruiting | Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers NCT04910386 | 3D Medicines (Sichuan) Co., Ltd. | Phase 2 |
| Not Yet Recruiting | Impact of Intraoperative PTCD Catheter Retention Versus Removal on Postoperative Short-term Outcomes After Pan NCT07532759 | Xu'an Wang | N/A |
| Recruiting | Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer NCT07146646 | Case Comprehensive Cancer Center | Phase 2 |
| Not Yet Recruiting | A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients Wit NCT07269158 | Yonsei University | Phase 1 / Phase 2 |
| Not Yet Recruiting | The Efficacy and Safety of Trilaciclib in Bone Marrow Protection Before Chemotherapy for Advanced Bile Duct Ca NCT07160283 | The Second Affiliated Hospital of Shandong First Medical University | Phase 2 |
| Not Yet Recruiting | The Safety and Efficacy of Benmelstobart Injection in Patients With Advanced Biliary Tract Malignant Tumors NCT07109167 | The Second Affiliated Hospital of Shandong First Medical University | Phase 2 |
| Recruiting | EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction (CARPEDIEM Trial) NCT06653192 | Hospital Universitari de Bellvitge | N/A |
| Recruiting | EUS-Gallbladder vs CDS as First Line in MBDO- Palliative (CARPEGIEM Trial) NCT06375967 | Hospital Universitari de Bellvitge | N/A |
| Recruiting | Personalized Medicine for Advanced Biliary Cancer Patients NCT05615818 | UNICANCER | Phase 3 |
| Recruiting | Agnostic Therapy in Rare Solid Tumors NCT06638931 | Instituto do Cancer do Estado de São Paulo | Phase 2 |
| Not Yet Recruiting | EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction in Resectable Disease NCT06375928 | Hospital Universitari de Bellvitge | N/A |
| Not Yet Recruiting | EUS-guided CDS vs ERCP as First Line in Malignant Distal Obstruction in Borderline Disease (CARPEDIEM-2 Trial) NCT06375954 | Hospital Universitari de Bellvitge | N/A |
| Not Yet Recruiting | Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectabl NCT06037655 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Not Yet Recruiting | The Construction of Clinical Database and Multiomics Biobank Based on a Multicentral Prospective Cohort of Ben NCT05896956 | RenJi Hospital | — |
| Unknown | Impact of a European Training Program for Robotic Liver Surgery (LIVEROBOT) NCT05723705 | Amsterdam UMC, location VUmc | — |
| Unknown | Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cance NCT05935579 | Peking Union Medical College Hospital | Phase 2 |
| Completed | Comparison of Duodenoscope With Single-use Distal Cover and the Conventional Reusable Duodenoscope NCT05429203 | Stanford University | N/A |
| Unknown | Transparent Cap-assisted SpyGlass for Biliary Stricture NCT05320497 | Affiliated Hospital to Academy of Military Medical Sciences | N/A |
| Terminated | Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With NCT04566133 | National Cancer Institute (NCI) | Phase 2 |
| Completed | TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer NCT05190575 | Shanghai Zhongshan Hospital | Phase 2 |
| Unknown | A Prospective Study of UCAD for Diagnosing Benign or Malignant Biliary Obstruction and Follow-up NCT05237193 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | — |
| Recruiting | Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) NCT04956640 | Eli Lilly and Company | Phase 1 / Phase 2 |
| Active Not Recruiting | Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations NCT04579380 | Seagen, a wholly owned subsidiary of Pfizer | Phase 2 |
| Completed | LAMS Choledochoduodenostomies: With or Without Coaxial Plastic Stent NCT04595058 | Hospital Universitari de Bellvitge | N/A |
| Unknown | A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical NCT04856761 | Fudan University | — |
| Active Not Recruiting | Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics NCT04584008 | Peking University | N/A |
| Completed | Preventing Viral Pandemic Associated Risk of Cancer Death Using Less Invasive Diagnostic Tests- Liquid Biopsie NCT04566614 | Royal Marsden NHS Foundation Trust | — |
| Active Not Recruiting | Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer NCT04308174 | Asan Medical Center | Phase 2 |
| Unknown | Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors NCT04010071 | Peking Union Medical College Hospital | Phase 2 |
| Unknown | Primary Hepatobiliary Cancer Cohort of Central China NCT05520801 | Tongji Hospital | — |
| Active Not Recruiting | Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tra NCT03875235 | AstraZeneca | Phase 3 |
| Recruiting | Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers NCT03801083 | Udai Kammula | Phase 2 |
| Completed | Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer NCT03406299 | National Health Research Institutes, Taiwan | Phase 2 |
| Active Not Recruiting | Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC NCT03478488 | 3D Medicines (Sichuan) Co., Ltd. | Phase 3 |
| Unknown | Analgesic Efficacy After Pancreatobiliary Surgery: Intravenous Versus Patient-controlled Epidural NCT04352023 | National Cancer Center, Korea | Phase 2 |
| Unknown | Apatinib for Advanced Biliary Carcinoma NCT03427242 | Fudan University | Phase 2 |
| Terminated | CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physicia NCT02900248 | CureOne | — |
| Completed | Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresect NCT03101566 | University of Michigan Rogel Cancer Center | Phase 2 |
| Completed | Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in NCT03111732 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Trac NCT03046862 | Seoul National University Hospital | Phase 2 |
| Unknown | The Effect of Individualized Precision Therapy Programs in Patients With BTC NCT02943031 | RenJi Hospital | Phase 4 |
| Unknown | EUS BD vs ERCP TP for Pancreatic Cancer NCT03063554 | Weill Medical College of Cornell University | N/A |
| Completed | Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers NCT02829918 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | Clinical Outcomes of Preoperative and Postoperative Rehabilitation in the Patients With HBP Malignancy NCT02784353 | Asan Medical Center | N/A |
| Completed | A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With NCT02821754 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | The Role of ctDNA and PBMC in Treatment of Biliary Tract Cancer NCT02809898 | RenJi Hospital | — |
| Unknown | Precise Treatment in Hepatobiliary Cancers (PTHBC) NCT02715089 | Peking Union Medical College Hospital | — |
| Terminated | Mid-Atlantic Research Group Single-Operator Cholangioscopic Assessment of Biliary Strictures NCT02615210 | Temple University | N/A |
| Completed | Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tra NCT02558959 | Zhejiang University | Phase 2 |
| Unknown | Fully Covered SEMS Versus Partially Covered SEMS With Anti-migration System for Malignant Distal Biliary Obstr NCT02255669 | Samsung Medical Center | N/A |
| Completed | Evolution® Biliary Stent System Clinical Study NCT01962168 | Cook Group Incorporated | — |
| Recruiting | Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma NCT01950572 | National Cancer Institute (NCI) | — |
| Completed | Tremelimumab With Chemoembolization or Ablation for Liver Cancer NCT01853618 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Radiofrequency Ablation for Malignant Biliary Obstruction NCT01758341 | Medical University of Vienna | Phase 4 |
| Completed | Nonstented Stump-closed vs Duct-to-Mucosa Pancreaticojejunostomy After Pancreaticoduodenectomy NCT01731821 | Fudan University | Phase 3 |
| Completed | ABC-04 a Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract Cancer NCT01242605 | University College, London | Phase 1 |
| Terminated | Endoscopic Therapy of Malignant Bile Duct Strictures NCT01543607 | Massachusetts General Hospital | N/A |
| Unknown | Duct-to-mucosa Versus Invagination for Pancreaticojejunostomy NCT01695447 | TingBo Liang | N/A |
| Completed | Cediranib Versus Placebo Plus Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Canc NCT00939848 | University College, London | Phase 2 / Phase 3 |
| Completed | Covered vs. Uncovered SEMS for Occluded Biliary Metal Stents NCT01315522 | Seoul National University Hospital | Phase 4 |
| Completed | The Diagnostic Value of Combinatory EUS and ERCP in Unclear Lesions NCT03504293 | Sahlgrenska University Hospital | — |
| Completed | RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction NCT00980889 | Stockholm South General Hospital | Phase 4 |
| Withdrawn | Comparing Endoscopic Based Stent Strategy Versus Bypass Surgery in Non-resectable Periampullary Cancer NCT00487851 | Karolinska Institutet | Phase 2 |
| Completed | Endoscopic Stenting of Gastrointestinal Cancer NCT00422409 | Ullevaal University Hospital | N/A |
| Terminated | A Randomized Trial of Two Surgical Techniques for Pancreaticojejunostomy in Patients Undergoing Pancreaticoduo NCT00359320 | Thomas Jefferson University | N/A |
| Completed | Portal Vein Stenting for Malignant Obstruction: Feasibility, Safety, and Clinical Outcomes NCT07252570 | Centre Hospitalier Universitaire de Nice | — |
| Completed | Malignant Obstruction ZILVER Against Routine Therapy (MOZART I) NCT00196105 | Cook Group Incorporated | N/A |
| Completed | EXIBIT: Oxaliplatin in Biliary Tract Cancer NCT00174564 | Sanofi | Phase 2 |
| Completed | The Efficacy and Safety of Gemcitabine in Combination With Docetaxel to Treat Pancreatic or Biliary Cancer NCT00268840 | ARCAGY/ GINECO GROUP | Phase 2 |